Collaborator Presented New Data at ESMO 2019 Congress
Dr. Tao Fu, from Gastrointestinal Surgery Department, Peking University Cancer Hospital, presented new data at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
AccuraGen, as the main collaborator in Dr. Fu’s clinical study, provided whole-exome sequencing (WES) and ctDNA-NGS sequencing for this project. This new data supported AccureGen’s technology to predict neoadjuvant chemotherapy therapeutic efficacy by circulating tumor DNA in gastric cancer patients.
Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer
To verify the value of ctDNA and CTC as biomarkers for tumor response in the neoadjuvant chemotherapy (nCRT) treatment of locally advance gastric adenocarcinoma.
A total of 50 patients were enrolled. 20ml of plasma were collected at 3 points: before nCRT; after 2 cycles of nCRT; and after surgery. Firefly ctDNA-NGS assays were used to track ctDNA mutations previously. Using patient-specific mutation derived from exome sequencing of tumor tissues samples. Tumor response data by CT were also collected. CTCs in 7ml peripheral blood were also separated by a negative enrichment method and identified by FISH.
A total of 10-20 somatic SNV or indel mutation were successfully identified for each patient. In comparison to basalline value of pre-chemotherapy blood, the ctDNA loading were decreased in post-chemotherapy specimens of 8 patients with TRG1 by histopathological grading or partial and complete response by CT scan.